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ABSTRACT 
Objective: Hot-melt extrusion technique (HME) was used to prepare a sustained release (SR) multiparticulate oral dosage form (pellets) containing 
Ibuprofen (IBU). Prepared IBU-HME pellets were in vitro evaluated by flow-through cell dissolution tester (FTC, USP Apparatus #4) using different 
flow conditions and FTC designs.  
Methods: In this study, Sucroester®
Results: The results showed that the IBU release rate was increased in the larger cell than the small cell. In addition, laminar flow showed more 
reproducible results than turbulent flow. It was found that the large cell with laminar flow rate and homogeneous mixing of the pellets with glass 
beads was the optimum conditions for in vitro evaluation of these preparations.  
WE15 was used as the polymeric carrier to prepare two different IBU loadings (60 % and 30 % w/w). In order 
to optimize the FTC conditions, different cell sizes, pellets loading and hydrodynamic conditions of FTC on IBU release rate from pellets were 
proposed.  
Conclusion: Improper methods of sample loading as well as cell size may result in confusing or erroneous data if not analyzed carefully. Therefore, 
it might be critical to choose a specific cell design of the FTC for in vitro evaluation of pellets to obtain reliable and discriminative results reflecting 
the major as well as minor formulation variables. 
Keywords: Ibuprofen, Flow-through cell, Hot-melt extrusion, Pellets, Sustained-release, Sucroester. 
 
INTRODUCTION 
IBU is a chiral nonsteroidal anti-inflammatory drug (NSAID) which 
is currently administered as racemate. It has proven over more than 
50 years to be safe and effective as a potent inhibitor of 
prostaglandin synthesis with the S-(+)-enantiomer possessing the 
majority of pharmacological activity. The absorption of IBU is rapid 
and complete when gave orally but suffers from short biological half 
life, approximately 2 h, thus require multiple daily dosing. 
Administration of SR dosage forms reduces the frequency of drug 
administration and maintains plasma concentration within the 
therapeutic range, thus enhancing patient compliance [1]. 
According to Biopharmaceutics Classification System (BCS), IBU is 
classified as class II (poorly soluble, highly permeable) [2]. 
Therefore, an enhancement of the dissolution rate of the drug is 
thought to be a key factor in improving the bioavailability of BCS 
Class II drugs [2]. IBU has been prepared in SR dosage forms such as 
tablets [3,10]. Capsules [11,13] and pellets [14,15] using different 
manufacturing techniques.  
Multiparticulate (MP) drug delivery systems give many advantages 
over the single-unit dosage forms due to their small size. MP systems 
improve the therapeutic efficiency, reduce the adverse effects and 
limit the risk of local irritation resulting in a more patient 
compliance. Moreover, MP systems achieve a unique release pattern 
with no risk of dose dumping [16]. However, studies on IBU in the 
form of pellets were very few in literature [14,15]. One of the recent 
preparation of MP drug delivery systems in the form of pellets is the 
use of HME technique [17,18]. 
HME is recently used as an alternative method for preparation of 
solid dispersions instead of the conventional methods such as 
melting and solvent evaporation methods, hence HME processed in 
the absence of solvents or water. Solid dispersions have shown 
promising future for both increasing the bioavailability of drugs and 
for developing controlled-release preparations [19]. 
Moreover, HME technology is an innovative and viable approach in 
the preparation of various pharmaceutical drug delivery systems 
such as pellets, granules, immediate and modified release tablets, 
oral fast dissolving systems, transdermal and transmucosal delivery 
systems [20]. In HME technique, raw materials or blends can be 
mixed and extruded under defined conditions as a continuous 
process. 
Carriers used in hot melt extruded dosage forms can be classified 
into polymeric [e. g. Polyethylene glycol (PEG), polyethylene oxide 
(PEO) and Eudragit® (acrylates)] and non-polymeric carriers (e. g. 
Carnauba wax). The properties of the carrier material often dictate 
the processing conditions necessary for the production of the dosage 
unit. The physical and chemical properties of the carrier often 
modulate the release of the active compound from the final dosage 
form [20].  
Sucrose esters (SEs) are non-ionic surface active agents consisting of 
sucrose as hydrophilic moiety and fatty acids as lipophilic groups. 
They are used in HME technology, because of their low melting 
points but the information available on these carriers is not 
sufficient and further investigations are still needed. SEs have a wide 
range of hydrophilic–lipophilic balance (HLB) values, ranges from 1 
to 16. In most cases, SEs are used in melt technology to improve the 
bioavailability of poorly water soluble materials [21]. For example, 
Sucroester S1670 (HLB=16) has been utilized as a hydrophilic 
polymer to improve the dissolution rate of glybuzole [22]. In the 
present study Sucroester®WE15 (HLB=15) with melting point (60 
°C), will be used as a hydrophilic polymer with IBU for HME process. 
The use of polymeric carriers in HME might require the 
incorporation of a plasticizer into the formulation. Plasticizers are 
typically low molecular mass compounds capable of softening 
polymers to make them more flexible by decreasing the polymer 
glass transition temperature (Tg) and melt viscosity, resulting in 
reducing the drug and carrier degradation and improve the stability 
profile of the active compound. Thus, thermal stability of the 
individual compound is a prerequisite for the HME process [20]. IBU, 
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a low melting point drug (78 °C), has a plasticizing effect on 
Sucroester®
The aim of this study was to prepare IBU-Sucroester
WE15, hence lower the extrusion temperature favorably 
affecting the stability of both the drug and polymer [23]. 
®
MATERIALS AND METHODS 
WE15 
sustained release pellets by HME technique. IBU-HME pellets were 
in vitro evaluated by FTC. Different cell sizes (large and small), flow 
conditions (turbulent and laminar) and pellets loading into the FTC 
were investigated to select the optimum hydrodynamic conditions 
that are capable to discriminate between the different preparations. 
Materials 
Pure Ibuprofen (IBU) was kindly donated from Sigma Pharma, Cairo, 
Egypt. Sucroester®
Methods 
WE15 was obtained from Gattefose S. A., France. 
Sodium hydroxide pellets and potassium dihydrogen 
orthophosphate were purchased from Laboratory Rasayan, India. 
Methanol (HPLC grade, Prolabo, France) was used for stock solution 
preparation. Milli-Q purified water (Millipore Corp., Billerica, MA, 
USA) was used to prepare the dissolution medium. 
Preparation of IBU-HME Pellets 
HME was performed using ¼ inch single screw extruder with a 
single rod die (Randcastle Microtruder RC-025, Randcastle 
Extrusion Systems, Inc., USA). It has four heating zones [three 
cylinder heating zones and one die heating zone] (Figure 1). Two 
formulae P1 & P2 were prepared, the ratios of IBU: 
Sucroester®WE15 were (60: 40 % w/w) and (30: 70 % w/w) for P1 
and P2, respectively. For each formula, IBU and Sucroester®
 
WE15 
were weighed in their specified ratios and physical mixtures were 
prepared by blending simultaneously, using polyethylene bag [24] 
for 10 minutes and then hot melt extruded. The four zones of the 
extruder were heated to the required temperatures ranges from 55-
65 °C and cooled by water. The extrusion temperature was well 
below the drug’s melting point (78 °C) and also below its 
decomposition temperature. Once the extrusion temperature was 
reached, the screw speed was set at 30 rpm and melt extrusion was 
started. The produced ‘spaghetti-like’ shape extrudates were cut 
manually into pellets of 2 mm length. 
 
Fig. 1: Schematic diagram of the single screw extruder 
(Randcastle Extrusion Systems, Inc., USA). 
 
UV-Spectrophotometric analysis of IBU 
A standard curve ranging from 0.5 to 35 μg/ml in phosphate buffer 
(pH 7.2) was constructed. A stock solution was prepared by 
dissolving 0.05 g of IBU powder in 100 ml methanol to yield a 
concentration of 500 μg/ml. This solution was serially diluted with 
phosphate buffer (pH 7.2) to yield the desired concentration range. 
The absorbance of the prepared solutions was measured 
spectrophotometrically (DU–650 UV-Vis spectrophotometer, 
Beckman, DU-650, USA) at λmax
Flow-through dissolution Tester 
 of 221 nm against a blank of 
phosphate buffer (pH 7.2). The absorbance was plotted against the 
concentration and the response factor was calculated. Each 
concentration was analyzed in triplicate and the mean values were 
calculated. A linear zero intercept relationship was established 
where the slope and regression coefficient were 0.0095 and 0.9986, 
respectively. Percent recoveries ranged from 85.18 % to 114.10 % 
and the average response factor was 19.97 ± 1.68. 
These studies were carried out using the FTC, USP Apparatus # 4, 
which is composed of Dissotest CE-6 equipped with a CY 7-50 piston 
pump (Sotax, Switzerland). Figure 2 describes the dissolution cell 
which could help in better understanding of the various IBU-HME 
pellets loading designs used in this study. It has 3 parts: the entry 
cone in which a rubby bead (6 mm diameter) was placed, the middle 
cylindrical portion and the filter head on top.  
Dissolution medium enters the cone through a capillary pore on the 
bottom and flows up the cell [25]. A built-in filtration system, in the 
filter head, with 0.7-μm Whatman glass microfiber (GF/F and GF/D) 
and glass wool was used throughout the study. The dissolution 
medium used throughout the experiments was filtered (0.45 µm), 
degassed (vacuum filtration system, Millipore, USA) phosphate 
buffer of pH 7.2 and its temperature was kept at 37 ± 0.5 °C. 
 
 
Fig. 2: Schematic diagram of the dissolution cell in the FTC 
apparatus. 
 
The prepared IBU-HME pellets (P1 & P2) were loaded into the FTC 
in five different designs (Figure 3) as follows:  
Design-A 
IBU-HME pellets were loaded in the small cell (12 mm) without glass 
beads (turbulent flow). 
Design-B 
IBU-HME pellets were loaded in the large cell (22.6 mm) without 
glass beads (turbulent flow).  
Design-C  
IBU-HME pellets were loaded in the entry cone of the large cell (22.6 
mm) with 1-mm round glass beads fill only the cylindrical portion of 
the cell (turbulent flow limited to a defined volume of the cell). 
Design-D  
IBU-HME pellets were loaded in the large cell (22.6 mm) 
homogeneously mixed with glass beads (ratio of pellets to glass 
beads 1: 2, respectively) (v: v). Mixing was carried out very gently 
with the help of a spatula then glass beads were added till the score 
of tablet holder [26].  
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IBU-HME pellets were loaded as design D but the glass beads fill the 
whole cell volume then covered with wide and narrow meshes. 
 
 
Fig. 3: Schematic diagrams showing the five designs for IBU-
HME pellets loaded into the FTC. 
 
The amount of pellets weighed in each cell was equivalent to 400 mg 
of pure IBU. All experiments were carried out in a closed-loop setup, 
using 900 ml filtered degassed phosphate buffer of pH 7.2 as 
dissolution medium with flow rate of 8 ml/min. Sample fractions 
were collected every half-hour for the first 2 h then every hour till 8 
h. At predetermined time intervals, volume fractions were collected 
and then analyzed spectrophotometrically for IBU content by 
measuring the absorbance at the corresponding λmax
Comparison between different FTC Designs 
 (221 nm) 
against phosphate buffer (pH 7.2) as blank. Each formula was tested 
in triplicate for up to 8 h and the mean value was calculated.  
The similarity factor (ƒ2), as proposed by Moore and Flanner [27] 
was calculated from the mean release data and was used to compare 
between different FTC designs. (ƒ2)  
ƒ
is defined as:  
2 
where, n is number of data time points collected during the in vitro 
release test, Rt and Tt are the cumulative percentages release at the 
selected (n) time points. The (ƒ
= 50 x log {[1+ (1/n) Σt=1n (Rt – Tt) 2 ]-0.5 x 100} 
2) value is a measure of similarity 
between two release profiles and its value ranges from 0 and 100. 
FDA has set a public standard of (ƒ2
RESULTS AND DISCUSSION 
) value of 50-100 to indicate 
similarity between two dissolution profiles [27]. 
In this study, SEs with high HLB values were used to increase or 
sometimes to slowdown drug release [21]. P1 & P2 pellets were 
prepared by extrusion of IBU with Sucroester®WE15 (HLB= 15) 
which was used as a hydrophilic polymeric carrier to sustain the IBU 
release. 
It is critical that the dissolution method employed be capable of 
demonstrating the extent of improvement in release that may be 
achieved by different formulation variables. Available evidence has 
shown that dissolution testing provides the means to evaluate 
critical parameters, such as bioavailability and provides information 
necessary to the formulator in developing more efficacious and 
therapeutically optimal dosage forms [28]. 
FTC dissolution apparatus (USP Apparatus # 4) offers a viable 
option for carrying out release of various dosage forms such as 
tablets, powders, suppositories, hard gelatin capsules, implants, 
semisolids and drug-eluting stents [29]. It offers a distinct advantage 
compared to USP paddle and basket apparatuses especially for drugs 
with poor solubility and wettability [28]. It solves the problem of 
non-sink conditions by supplying an unlimited quantity of fresh 
dissolution medium [30].  
Moreover, FTC is specially designed to have a small holdup volume 
compared with other USP dissolution apparatuses that helps to 
minimize spreading of drug particles to undefined sites of the 
apparatus. This adjustment could eliminate or minimize the errors 
of highly variable release profiles that might be obtained from the 
conventional dissolution apparatuses (Basket & Paddle) [25]. Also, it 
assures that the tests are carried out under well-controlled 
conditions of agitation and uninterrupted sampling that are capable 
of discriminating between products and detecting any formulation 
changes that might affect drug bioavailability.  
However, there have been few reports in literature regarding the 
testing of pellets using the FTC [31,32]. Also, no systematic 
evaluation of pellets loading into the FTC, to detect any formulation 
changes as well as the reproducibility of the results has been 
described.  
In our study, IBU-HME pellets (P1 & P2) containing different IBU 
concentrations were loaded into the FTC according to different 
designs as illustrated in Figure 3 and the impact of the loading 
pattern on IBU release rate was studied. 
Figures 4-8 showed the release rate profiles of the two formulae P1 
& P2 containing 60 % and 30 % IBU, respectively loaded into the 
FTC according to designs (A-E). Error bars on the graphs represent 
the standard deviation (S. D.) of the mean (n=3). When the pellets 
were loaded according to design-A, under the turbulent flow, the IBU 
released after 8 h was the lowest for P1 & P2 (35 % and 28 %, 
respectively) as shown in Figure 4. On the other hand, when the 
pellets were loaded according to design-B, the IBU released was the 




Fig. 4: Release profiles of IBU-HME pellets loaded into the FTC 
according to design-A 
 
 
Fig. 5: Release profiles of IBU-HME pellets loaded into the FTC 
according to design-B 
 
These results showed that the IBU released was lower in the small 
cell than in the large cell, which could be attributed to the 
phenomena of pellets agglomeration which was observed in the 
small cell during the dissolution testing. These agglomerates 
retained a lot of air bubbles between pellets which decrease the 
surface area exposed to the dissolution medium and hence low IBU 
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was released. While using the large cell allowed larger space for 
pellets and eliminated pellets agglomeration, which might increase 
IBU release rate. However, these designs (A & B) suffered from bad 
reproducibility as indicated by the high S. D. values (Figures 4 & 5).  
These results were not in agreement with previous studies done 
[28,33,34]. A study was carried out on Voltaren Retard tablets 
where the cell size (small or large) had almost no effect on the 
release of diclofinac sodium [28]. The dissolution rates of nifedipine 
from commercially available controlled-release tablets in the large 
cell were significantly lower than those in the small cell [33]. 
Similarly, Cammaran et al [34] reported that the dissolution rate of 
salicylic acid tablets in the large cell was significantly lower than 
those in the small cell. This was explained by the fact that, the fresh 
dissolution medium was recirculated faster in the small cell, 
resulting in more drug diffusion, which was expected to increase the 
amount of drug in the small cell [34]. It is worthy to mention here 
that the dosage forms previously studied were tablets [28,33,34], 
while in our study the dosage form was pellets which might require 
special FTC design. 
In case of applying the large cell with turbulent flow limited to a 
defined volume of cell (design-C), the IBU released was almost the 
same for both P1 & P2 (49.94 % and 50.25 %, respectively) as 




Fig. 6: Release profiles of IBU-HME pellets loaded into the FTC 
according to Design-C 
 
However, P1 contained a double amount of IBU than P2 (60 % and 
30 % w/w, respectively), this design did not reflect this large drug 
loading difference. Comparing designs B & C, it was clear that the 
IBU released from P1 & P2 was drastically decreased (from 89 % 
and 67 % to 49.94 % and 50.25 %, respectively) as shown in Figures 
5 & 6. On the other hand, a study on Volatren Retard tablets [28] 
showed similar release profiles of diclofenac sodium when the tablet 
was loaded into the FTC using the same cell designs (B & C). Again, 
we should report that the use of different dosage forms might 
require modification of the FTC. 
Therefore, designs (A, B & C) were not appropriate for IBU-HME 
pellets loading into the FTC. These unexpected results led to the 
exploration of alternative designs of sample loading in order to 
achieve acceptable release data capable to discriminate between 
different formulations with low variability of a results by applying 
the laminar flow instead of the turbulent flow.  
Accordingly, the pellets were loaded according to design-D under 
laminar flow conditions. Figure 7 showed that the IBU released from 
P1 & P2 were found to be 64 % and 46 %, respectively.  
The release of IBU from P2 pellets showed a relatively bad 
reproducibility of results as indicated by the high S. D. Values. It was 
observed that, in case of P2, after 1 h of release, some pellets 
migrated over the glass beads and swelled in the free part of the cell 
which might be the reason of the bad reproducibility of the release 
rate results. To overcome the migration of pellets to undefined sites 
in the cell, additional amount of glass beads was used to fill the 
whole cell volume and covered with wide and narrow meshes as 
shown in (design-E). Figure 8 showed the release rates of plain IBU 
powder as well as P1 and P2. The IBU powder showed a burst 
release in the first hour (80 %) then almost a plateau for 7 h, while 
IBU released was 65 % and 47 %, for P1 and P2, respectively. 
 
 
Fig. 7: Release profiles of IBU- HME pellets loaded into the FTC 
according to design-D 
 
 
Fig. 8: Release profiles of IBU powder, P1 and P2 pellets loaded 
into the FTC according to design-E 
 
Although, IBU released in both designs (D & E) from P1 & P2 was 
almost the same, design-E showed reproducible results as indicated 
by the very low S. D. values for both P1 & P2. This result agreed with 
a previous study [25] on a poorly soluble compound using different 
designs of powder loading within the glass beads into the FTC and 
their impact on its dissolution. It was reported that homogeneous 
mixing of the drug powder with glass beads was the best method of 
drug loading into the cell. 
This result showed that the Sucroester®WE15 succeeded in 
sustaining the IBU release rate from P1 & P2 compared to the IBU 
powder (Figure 8). On the other hand, Sucroester®
Design-E was selected as the best design to carry out future in vitro 
release studies for IBU-HME pellets. The advantages of this design 
were as follows: it achieved the optimum conditions for IBU release 
from the proposed formulations, solved the problems of unreliable 
release data due to spreading of pellets to undefined sites of the cell 
and thereby, eliminated the resulting errors in the release data and 
finally, achieved maximum release with minimum variability of 
results.  
WE15 has been 
used with HME in previous studies to enhance the release of 17-
estradiol [35] and Nifedipine [33]. 
Moreover, design-E was able to discriminate between the two 
formulae P1 & P2 containing different IBU loading (60 % and 30 %, 
respectively), so it reflected the very important formulation 
difference: the drug loading. Therefore, it might be crucial to design 
a specific cell design for each drug and/or dosage form upon using 
the FTC apparatus.  
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Figures 9 and 10 summarized the impact of different designs of the 
FTC on the release rate of IBU for each formula, which showed the 
variability within the same test sample due to FTC design change. In 
order to figure out to what extent the different designs could affect 
the IBU release within each formula, (f2) was calculated to show the 
similarity or dissimilarity of IBU release profiles obtained from each 
design. Table 1 recorded the similarity factor (f2
 
) of IBU release 
profiles between the selected design-E set as reference, against the 
other four designs (A-D). In case of P1, the designs (A, B & C) showed 
dissimilar release profiles. In a case of P2, designs (A & B) showed 
dissimilar release profiles. 
 
Fig. 9: Release profiles of P1 pellets loaded into the FTC 
according to designs (A-E) 
 
 
Fig. 10: Release profiles of P2 pellets loaded into the FTC 
according to designs (A-E) 
 
Table 1: Similarity factors (f2
Formula 
) values between the selected 
design-E set as reference, against other designs (A-D). 
IBU (% w/w) ƒ2 values 
FTC designs 
 A B C D 
 P1  60  30 44 42 91 
 P2   30  41 47 82 93 
 
CONCLUSIONS 
To successfully employ the FTC for evaluating MP dosage forms, it is 
critical that the drug substance be maintained in the body of the cell 
during testing. As seen from this study, this was not simple to 
achieve and optimize the FTC conditions with pellets. In the absence 
of a better cell design, the method of sample preparation and loading 
into the cell need to be carefully chosen in order to obtain reliable 
results. The intent of this work was to determine how well this 
method of release testing and the design of pellets loading can 
discriminate between 60 % and 30 % w/w IBU loadings. Achieving 
100 % of IBU release, although desirable, was not set as a goal. The 
data presented demonstrates that for a MP/IBU delivery system, 
design E was the design of choice. Improper methods of sample 
loading as well as cell size may result in confusing or erroneous data 
if not analyzed carefully. 
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